Abstract
Chronic pain is a very disturbing condition and to date, no effective and safe medicine has been found. This could be caused by existing drugs not targeting the key factor in pain transmission. Cdk5 is a protein kinase that has been shown to have a key role in the transmission of chronic pain. These important roles include: activation of TRPV1, NMDA, P/Q type voltage-dependent calcium channels, and ATP-gate P2X receptors. Cdk5 could be used as a potential target in the development of new anti-chronic pain drugs. Several aspects of concern in developing this drugs are the role of Cdk5 in physiological and pathological conditions because it’s will be related to the risk of side effects. Another factor that really needs to be considered is the location of Cdk5 expression because it will related to the drug design. Several drugs that have been developed as Cdk5 inhibitors are roscovitin, olomoucine, and indirubin.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
